31 maj: Europa/luk: Tro på irsk "ja" banket ned af USA-tal
01 jun: Selskabernes forventninger - fredag den 1 juni
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold
Relateret debat
29 mar - 
Dear Sir/Ma, We have direct providers for BG/SBLC speci..
19 mar - 
We have direct providers of Fresh Cut BG, SBLC and MTN ..
06 mar - 
Dear Sir/MA I Offer cut bank instrument for lease/sale,..

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Merck leverer bedre end ventet og opjusterer - NY

28-04-2015 13:22:27
Det amerikanske medicinalselskab Merck kom pænt ud af første kvartal, hvor selskabet leverede noget bedre end ventet på bundlinjen. Samtidig løfter Merck sin pr..

Aktier/middag: Bøtten vendt på hovedet for C20 Cap

28-04-2015 11:07:14
Gassen er gået af ballonen for de danske aktier tirsdag, efter at mandagen bød på rekord nummer 28 i 2015 for C20 Cap-indekset, der blev sendt til vejrs af oplø..

Aktier/tendens: Royal Unibrew i fokus i rødt Europa

28-04-2015 08:20:04
Regnskaber er på dagsordenen tirsdag i Europa, hvor selskaber som Philips, BP, Daimler, Swedbank, Total, TNT Express og Atlas Copco er til eksamen og kommer til..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Bøtten vendt på hovedet for C20 Cap
2
Aktier/tendens: Royal Unibrew i fokus i rødt Europa
3
Vind: Brasiliansk auktion skuffer fælt
4
Mandagens aktier: Græske toner sparker C20 Cap i rekord
5
Novo: Liraglutide kan måske anvendes til leversygdom - medie

Relaterede aktiekurser

Johnson & Johnson 99,55 -1,0% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. april 2015 16:26:52
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150424.2 - EUROWEB7 - 2015-04-28 16:26:52 - 2015-04-28 16:26:52 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x